Search - tctmd.com

Displaying 41 - 60 of 1111

Sort: Relevancy | Date

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Conference News EHRA 2025

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

Todd Neale

April 09, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

Yael L. Maxwell

January 23, 2025

News Daily News

EXCEL Data Highlight Bleeding Patterns After CABG, PCI for LM Disease

Yael L. Maxwell

December 05, 2024

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

Presenter: Hongbo Yang

October 30, 2024

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

Todd Neale

October 27, 2024

Presentation TCT 2024

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

Presenter: Woo Jin Jang

October 27, 2024

Advertisement

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

TCTMD’s Top 10 Most Popular Stories for March 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

What’s Going to Be Hot at ACC 2025?

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

ACC/AHA Release New Comprehensive ACS Guidelines

Ischemic vs Bleeding Risks: Do Antiplatelet Guidelines Need Rethinking?

EXCEL Data Highlight Bleeding Patterns After CABG, PCI for LM Disease

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

3-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of the Biodegradable Polymer Firehawk Sirolimus-Eluting Coronary Stent: Primary Outcomes of the TARGET DAPT Trial

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

LAAO Outcomes Similar Regardless of Operator’s Specialty

TCT 289: Different Efficacy of 12-Month Dual Antiplatelet Therapy Following Off-Pump Versus On-Pump Coronary Artery Bypass Grafting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content